{"entity":{"id":"nct07719361","kind":"trial","name":"A Study in Patients With Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 1 trial of FX-111 run by Flare Therapeutics Inc., now recruiting.","summary":"A Study in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT07719361 by Flare Therapeutics Inc., with 60 participants planned, started 2026-07-01, primary completion expected 2028-02-15. Conditions recorded: Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, mCRPC or Advanced/Metastatic Solid Tumors, mCRPC, Metastatic Castration Resistant Prostate Cancer, Neoplasms Prostate, Neoplasms of Prostate. Interventions recorded: FX-111.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07719361","url":"https://clinicaltrials.gov/study/NCT07719361"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["fx-111"],"companies":["flare-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07719361","phase":"1","setting":"A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Flare Therapeutics Inc.","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07719361/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"fx-111","kind":"drug","name":"FX-111","route":"/drugs/fx-111/"}],"company":[{"id":"flare-therapeutics","kind":"company","name":"Flare Therapeutics","route":"/companies/flare-therapeutics/"}]}}